 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- GS-1427 / Gilead
PHASE 1 BIOMARKER ANALYSES OF GS-1427 A NOVEL ORAL ?4?7 INTEGRIN INHIBITOR FOR INFLAMMATORY BOWEL DISEASE DEMONSTRATE ?4?7 SELECTIVITY AND ONCE DAILY DOSING (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_1611;
In conclusion, the exploratory biomarker results in this Phase 1 study in healthy subjects demonstrating extended ?4?7 RO and ?4?7 selectivity together with the pharmacokinetics, safety, and tolerability data (abstract in preparation) support further development of GS-1427 with a once daily dosing regimen in a Phase 2 study in IBD.
- |||| GS-1427 / Gilead
Enrollment open, Combination therapy, Monotherapy: SWIFT: Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Apr 2, 2024
P2, N=423, Recruiting, Sponsor: Gilead Sciences
In conclusion, the exploratory biomarker results in this Phase 1 study in healthy subjects demonstrating extended ?4?7 RO and ?4?7 selectivity together with the pharmacokinetics, safety, and tolerability data (abstract in preparation) support further development of GS-1427 with a once daily dosing regimen in a Phase 2 study in IBD. Not yet recruiting --> Recruiting
- ||||| GS-1427 / Gilead
New P2 trial, Combination therapy, Monotherapy: SWIFT: Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Mar 3, 2024
P2, N=423, Not yet recruiting, Sponsor: Gilead Sciences
- | GS-1427 / Gilead
New P1 trial: A Phase 1, Dose-Escalation Study in Healthy Volunteers to Evaluate the Pharmacokinetics, Safety, and Tolerability of GS-1427 Following Single and Multiple Dosing (EUDRACT) - Aug 27, 2021
P1, N=110, Not yet recruiting, Sponsor: Gilead Sciences